Author

D. Lozano-Ojalvo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

E. Guccione· 2 shared A. Bertoletti· 1 shared A. Ortiz· 1 shared A. Tsankov· 1 shared B. Giotti· 1 shared C. Berin· 1 shared C. Camara· 1 shared C. Company· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Guccione

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Mutation-driven oncofetal regression fuels phenotypic plasticity in colorectal cancer

S. Mzoughi, M. Schwarz, X. Wang, D. Demircioglu, G. Ulukaya, K. Mohammed, F. Di Tullio, C. Company, Y. Dramaretska, M. Leushacke, B. Giotti, T. Lannagan, D. Lozano-Ojalvo, D. Hasson, A. Tsankov, , E. Guccione

This study identifies an oncofetal cell state that contributes to resistance in colorectal cancer and shows that targeting both this state and LGR5+ CSCs is needed for effective treatment.

bioRxiv · Dec 10, 2023Cancer Biology

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

C. Camara, D. Lozano-Ojalvo, E. Lopez-Granados, E. Paz-Artal, M. Pion, R. Correa-Rocha, A. Ortiz, M. Lopez-Hoyos, M. Erro Iribarren, J. Portoles, P. Portoles, M. Perez-Olmeda, J. Oteo-Iglesias, C. Berin, E. Guccione, , J. Ochando

This study examines how the second dose of the BNT162b2 vaccine affects T cell immunity in naive and previously infected individuals, finding reduced cellular immunity in recovered individuals.

bioRxiv · Mar 22, 2021Immunology